My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes : Episode 5
Opinion
Video
Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
Author(s):
Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.
EP: 1.Patient with Newly Diagnosed CLL with High-Risk Features
EP: 2.Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL
EP: 3.Navigating Continuous BTKi Therapy for CLL in the 1L Setting
EP: 4.Implications of Real-World Data in the 1L Treatment of High-Risk CLL
Now Viewing
EP: 5.Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
EP: 6.Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL
EP: 7.Perspectives on Shared Decision-Making in the Treatment of CLL
EP: 8.Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL
EP: 9.Expert Insights for Long-Term Treatment Planning in CLL
EP: 10.Patient with R/R CLL Treated with 2L Venetoclax Therapy
EP: 11.Navigating 2L Treatment Options in CLL
EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications
EP: 13.Management Strategies for BTKi-Related CVAEs in CLL
EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis
EP: 15.Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL
Video content above is prompted by the following questions:
- Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
Related Videos
Related Content
